Ingenuity Systems and Millennium Pharmaceuticals, Inc. Sign New Three-Year Deal


Drug Discovery Technology Conference, Boston, August 9, 2004 – Ingenuity today announced a three-year licensing agreement in which Ingenuity will provide software and custom services to Millennium Pharmaceuticals, Inc. This new relationship builds on the successful completion of the companies’ initial two-year collaboration announced in April 2002.

Two years ago, Millennium and Ingenuity established a collaboration to create groundbreaking solutions in the scientific knowledge management arena with the goal of enabling Millennium to better leverage the information it generates during the drug discovery and development process.

This new relationship will span three years and involves the licensing of Ingenuity’s next generation applications and development platform. New breakthrough features available in the IPA application are already being used by Millennium researchers to give them a competitive advantage and help them gain novel insights from their experimental results.

“The Ingenuity team delivers results that we have found to be extremely productive and critical in our R&D efforts,” stated Tom Scarnecchia, Vice President, Corporate Informatics, Millennium. “With Ingenuity’s expanding focus on the entire drug discovery and development process, the next three years promise to build on the successes of our original collaboration.”

“The Ingenuity solution increases productivity across R&D by reducing failures and saving time” commented Jake Leschly, CEO and President of Ingenuity. “Millennium has some of the brightest and best talent in this industry, and their continued use of the products and early involvement in our product development process means we can, together, continue to build the best software applications for driving R&D productivity.”

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California.